Disease areas
We have a long-standing commitment to addressing disease areas where we believe peptide therapies can make a difference for people living with unmet medical needs.
Obesity
Obesity and overweight is a complex chronic disease that requires long term management. More than 220 complications and co-morbidities, including cardiovascular disease, liver disease, type 2 diabetes, kidney disease, and neuroinflammation are associated with obesity.
Rare diseases
We are focused on two very different rare diseases where peptide-based therapies have potential to address significant unmet needs and improve lives: congenital hyperinsulinism (CHI) and short bowel syndrome (SBS)
Chronic inflammation
Chronic inflammation plays a role in many diseases and conditions that are leading causes of death worldwide.
Type 1 Diabetes
Achieving tight control over blood-glucose levels remains a daily challenge for those living with type 1 diabetes.
Patient stories
Crosby was born with CHI
Congenital Hyperinsulinism
Julie and her husband, knew during pregnancy that Crosby, would be born with congenital hyperinsulinism (CHI): an ultra-rare genetic disorder that causes the insulin cells of the pancreas, called beta cells, to secrete too much insulin. The disorder may cause Crosby to have cognitive and physical disabilities if not treated adequately.
READ MY STORYMarianne lives with Short Bowel Syndrome
Short Bowel Syndrome
Marianne was diagnosed with cancer of the small intestine and became a short bowel patient. Today, she manages to live a life on home parenteral nutrition and works as a pastor.
READ MY STORYMike gets back in the game while living with SBS
Short Bowel Syndrome
Dependent on parenteral support to survive, Mike must connect to infusion equipment for eight hours a day, six days a week. Reducing the complexity – and time spent – for parenteral support enabled this driven college football coach to get back in the game.
READ MY STORYWill works to reduce his need for parenteral support
Short Bowel Syndrome
After a stomach pain and a black out in his home, then 13-year old Will was rushed to a local hospital in New Jersey, where the doctors discovered a volvulus and most of his small intestine was removed.
READ MY STORYI hear from our employees every day how important it is to them that the work we do contributes to making a difference in peoples lives.
Christina Sonnenborg Bredal
Chief People Officer
Latest news
View all news-
Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism
READ MORE -
Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide
READ MORE -
Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024
READ MORE -
Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th
READ MORE